Symrise AG Stock Timeline

2026-07-30 — H1 2026 results; accelerating organic growth; portfolio moves

Symrise reported H1 2026 results showing accelerating growth in Q2 and announced portfolio transactions: a binding offer for the Floral Concept acquisition and a signed agreement to divest the Terpene Ingredients business to Mutares SE & Co. An inaugural €400m share buyback program announced earlier in 2026 was active. [7][1]

Market perception shifted toward "ONE Symrise" execution and portfolio-sharpening. Investors emphasized margin expansion, cash conversion and active capital allocation (buyback and continued dividend increases) rather than pure top-line acceleration. The Floral Concept move was seen as selective premium naturals M&A to lift product mix; the terpene divestment signaled portfolio pruning. [7][1]

Organic sales growth accelerated to 4.5% in Q2 2026 (2.0% in H1 2026). Adjusted EBITDA reached €553m with an adjusted EBITDA margin of 21.8%. Adjusted Business Free Cash Flow margin was 13.7% of sales. [2][7]

2026-03-04 — FY 2025 results announced

Symrise published FY 2025 results and 2026 guidance ranges. Management highlighted record adjusted Business Free Cash Flow and announced capital allocation priorities including a €400m share buyback program and a proposed dividend increase. [6][9]

Investors framed Symrise as a cash-generative specialty-chemicals and ingredients compounder with disciplined M&A and shareholder returns. The emphasis on record BFCF and buyback supported a valuation narrative focused on cash returns and margin improvement. [6][9]

Group sales reached €4,929 million for FY 2025 with organic sales growth of 2.8%. Adjusted EBITDA margin was 21.9% and adjusted Business Free Cash Flow hit a record €780 million (15.8% BFCF margin). For 2026, the company guided to organic growth of 2.0–4.0%, adjusted EBITDA margin of 21.5–22.5%, and BFCF margin above 14%. [6][9]

2025-07-30 — H1 2025 results; Executive Board appointment

Symrise reported first-half 2025 results and appointed Michael Friede as Executive Board Member and President of the Scent & Care segment. [15]

Management changes in the Scent & Care segment were seen as strengthening go-to-market and product leadership in a core margin-contributing segment. H1 performance and leadership appointments reinforced the company's "growth with margin" message. [15]

2024 — Continued post-pandemic recovery; focus on premiumization and naturals

Symrise continued executing growth initiatives throughout 2024 with strategic emphasis on premium naturals, sustainability and innovation. Corporate materials highlighted investments and segment focus. [10]

Investor perception was that Symrise was transitioning from pandemic-recovery volatility into a steady compounder driven by premiumization (naturals, fragrances, taste & nutrition) and margin management. Sustainability and product-portfolio premiumization were recurring themes in investor communications. [10]

2023 — Post-COVID demand normalization; organic growth pressures and margin actions

Symrise reported results reflecting normalization after pandemic disruption and raw-material and cost pressures. Management emphasized efficiency measures and value-based pricing. [8][10]

Investors saw 2023 as a year of margin-defense and working-capital management rather than aggressive growth; the story leaned toward a resilient specialty-ingredients operator protecting profitability and cash. [8][10]

2022 — Strong recovery year with notable revenue growth

Symrise reported a significant rebound in 2022 sales and growth following pandemic-related weakness in prior periods. [8]

Market perception shifted back toward growth, with investors expecting cyclical end-markets (flavors, fragrances, personal care) to recover and drive revenue expansion. The company's M&A and R&D positioning were framed as support for a durable growth trajectory. [8]

2021 — Pandemic-year pressures; revenue weakness and margin sensitivity

Symrise's 2021 reporting reflected lingering impacts of COVID-19 on certain end markets (fragrances, out-of-home flavors), leading to uneven top-line performance and heightened investor focus on margin resilience and cost management. [8]

Investors viewed 2021 as a stress-test year — the company was fundamentally a specialty-ingredients compounder but exposed to shifts in consumer demand. Attention centered on management execution to restore growth and margins. [8]